TrialBritish journal of cancer2017

A combined biomarker panel shows improved sensitivity for the early detection of ovarian cancer allowing the identification of the most aggressive type II tumours.

Matthew R Russell et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.